APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaccine Particulate Adjuvants

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vaccine Particulate Adjuvants Market Outlook and Growth Opportunities 2026

Report ID 174044850426 December 2025193 pages

Choose your research edition.

Industry ResearchVaccine Particulate Adjuvants Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Particulate Adjuvants Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Vaccine Particulate Adjuvants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Particulate Adjuvants Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Particulate Adjuvants Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Vaccine Particulate Adjuvants market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vaccine Particulate Adjuvants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaccine Particulate Adjuvants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaccine Particulate Adjuvants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vaccine Particulate Adjuvants market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vaccine Particulate Adjuvants market include Agenus, Inc(US), Avanti Polar Lipids, Inc(US), Brenntag Biosector (Denmark), CSL Limited (Australia), Invivogen (US), MVP Laboratories, Inc(US), Novavax, Inc(US), OZ Biosciences (France) and SEPPIC (France), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vaccine Particulate Adjuvants market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaccine Particulate Adjuvants and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine Particulate Adjuvants sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vaccine Particulate Adjuvants market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaccine Particulate Adjuvants Segment by Company

Agenus, Inc(US)

Avanti Polar Lipids, Inc(US)

Brenntag Biosector (Denmark)

CSL Limited (Australia)

Invivogen (US)

MVP Laboratories, Inc(US)

Novavax, Inc(US)

OZ Biosciences (France)

SEPPIC (France)

SPI Pharma, Inc(US)

Vaccine Particulate Adjuvants Segment by Type

Subcutaneous

Intradermal

Oral

Intramuscular

Intranasal

Others

Vaccine Particulate Adjuvants Segment by Application

Infectious Diseases

Cancer

Others

Vaccine Particulate Adjuvants Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Vaccine Particulate Adjuvants status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vaccine Particulate Adjuvants market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vaccine Particulate Adjuvants significant trends, drivers, influence factors in global and regions.

6. To analyze Vaccine Particulate Adjuvants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Particulate Adjuvants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine Particulate Adjuvants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Particulate Adjuvants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vaccine Particulate Adjuvants market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaccine Particulate Adjuvants industry.

Chapter 3: Detailed analysis of Vaccine Particulate Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vaccine Particulate Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vaccine Particulate Adjuvants in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vaccine Particulate Adjuvants Industry Trends Table 2. Vaccine Particulate Adjuvants Industry Drivers Table 3. Vaccine Particulate Adjuvants Industry Opportunities and Challenges Table 4. Vaccine Particulate Adjuvants Industry Restraints Table 5. Global Vaccine Particulate Adjuvants Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vaccine Particulate Adjuvants Revenue Share by Company (2021-2026) Table 7. Global Vaccine Particulate Adjuvants Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Vaccine Particulate Adjuvants Sales Volume Share by Company (2021-2026) Table 9. Global Vaccine Particulate Adjuvants Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Vaccine Particulate Adjuvants Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vaccine Particulate Adjuvants Key Company Manufacturing Base & Headquarters Table 12. Global Vaccine Particulate Adjuvants Company, Product Type & Application Table 13. Global Vaccine Particulate Adjuvants Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vaccine Particulate Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Subcutaneous Table 18. Significant Companies of Intradermal Table 19. Significant Companies of Oral Table 20. Significant Companies of Intramuscular Table 21. Significant Companies of Intranasal Table 22. Significant Companies of Others Table 23. Global Vaccine Particulate Adjuvants Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Vaccine Particulate Adjuvants Sales Volume by Type (2021-2026) & (W Units) Table 25. Global Vaccine Particulate Adjuvants Sales Volume by Type (2027-2032) & (W Units) Table 26. Global Vaccine Particulate Adjuvants Sales Volume Share by Type (2021-2026) Table 27. Global Vaccine Particulate Adjuvants Sales Volume Share by Type (2027-2032) Table 28. Global Vaccine Particulate Adjuvants Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Vaccine Particulate Adjuvants Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Vaccine Particulate Adjuvants Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Vaccine Particulate Adjuvants Sales Value Share by Type (2021-2026) Table 32. Global Vaccine Particulate Adjuvants Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Infectious Diseases Table 34. Significant Companies of Cancer Table 35. Significant Companies of Others Table 36. Global Vaccine Particulate Adjuvants Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Vaccine Particulate Adjuvants Sales Volume by Application (2021-2026) & (W Units) Table 38. Global Vaccine Particulate Adjuvants Sales Volume by Application (2027-2032) & (W Units) Table 39. Global Vaccine Particulate Adjuvants Sales Volume Share by Application (2021-2026) Table 40. Global Vaccine Particulate Adjuvants Sales Volume Share by Application (2027-2032) Table 41. Global Vaccine Particulate Adjuvants Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Vaccine Particulate Adjuvants Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Vaccine Particulate Adjuvants Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Vaccine Particulate Adjuvants Sales Value Share by Application (2021-2026) Table 45. Global Vaccine Particulate Adjuvants Sales Value Share by Application (2027-2032) Table 46. Global Vaccine Particulate Adjuvants Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Vaccine Particulate Adjuvants Sales by Region (2021-2026) & (W Units) Table 48. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2021-2026) Table 49. Global Vaccine Particulate Adjuvants Sales by Region (2027-2032) & (W Units) Table 50. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2027-2032) Table 51. Global Vaccine Particulate Adjuvants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Vaccine Particulate Adjuvants Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Vaccine Particulate Adjuvants Sales Value Share by Region (2021-2026) Table 54. Global Vaccine Particulate Adjuvants Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Vaccine Particulate Adjuvants Sales Value Share by Region (2027-2032) Table 56. Global Vaccine Particulate Adjuvants Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Vaccine Particulate Adjuvants Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Vaccine Particulate Adjuvants Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Global Vaccine Particulate Adjuvants Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (W Units) Table 61. Global Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2026) Table 62. Global Vaccine Particulate Adjuvants Sales by Country (2027-2032) & (W Units) Table 63. Global Vaccine Particulate Adjuvants Sales Market Share by Country (2027-2032) Table 64. Global Vaccine Particulate Adjuvants Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Vaccine Particulate Adjuvants Sales Value Market Share by Country (2021-2026) Table 66. Global Vaccine Particulate Adjuvants Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Vaccine Particulate Adjuvants Sales Value Market Share by Country (2027-2032) Table 68. Agenus, Inc(US) Company Information Table 69. Agenus, Inc(US) Business Overview Table 70. Agenus, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Agenus, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 72. Agenus, Inc(US) Recent Development Table 73. Avanti Polar Lipids, Inc(US) Company Information Table 74. Avanti Polar Lipids, Inc(US) Business Overview Table 75. Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 77. Avanti Polar Lipids, Inc(US) Recent Development Table 78. Brenntag Biosector (Denmark) Company Information Table 79. Brenntag Biosector (Denmark) Business Overview Table 80. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Portfolio Table 82. Brenntag Biosector (Denmark) Recent Development Table 83. CSL Limited (Australia) Company Information Table 84. CSL Limited (Australia) Business Overview Table 85. CSL Limited (Australia) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. CSL Limited (Australia) Vaccine Particulate Adjuvants Product Portfolio Table 87. CSL Limited (Australia) Recent Development Table 88. Invivogen (US) Company Information Table 89. Invivogen (US) Business Overview Table 90. Invivogen (US) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Invivogen (US) Vaccine Particulate Adjuvants Product Portfolio Table 92. Invivogen (US) Recent Development Table 93. MVP Laboratories, Inc(US) Company Information Table 94. MVP Laboratories, Inc(US) Business Overview Table 95. MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 97. MVP Laboratories, Inc(US) Recent Development Table 98. Novavax, Inc(US) Company Information Table 99. Novavax, Inc(US) Business Overview Table 100. Novavax, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Novavax, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 102. Novavax, Inc(US) Recent Development Table 103. OZ Biosciences (France) Company Information Table 104. OZ Biosciences (France) Business Overview Table 105. OZ Biosciences (France) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. OZ Biosciences (France) Vaccine Particulate Adjuvants Product Portfolio Table 107. OZ Biosciences (France) Recent Development Table 108. SEPPIC (France) Company Information Table 109. SEPPIC (France) Business Overview Table 110. SEPPIC (France) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. SEPPIC (France) Vaccine Particulate Adjuvants Product Portfolio Table 112. SEPPIC (France) Recent Development Table 113. SPI Pharma, Inc(US) Company Information Table 114. SPI Pharma, Inc(US) Business Overview Table 115. SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 117. SPI Pharma, Inc(US) Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Vaccine Particulate Adjuvants Distributors List Table 121. Vaccine Particulate Adjuvants Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Vaccine Particulate Adjuvants Product Image Figure 2. Global Vaccine Particulate Adjuvants Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Particulate Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vaccine Particulate Adjuvants Sales (2021-2032) & (W Units) Figure 5. Global Vaccine Particulate Adjuvants Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Vaccine Particulate Adjuvants Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Subcutaneous Image Figure 10. Intradermal Image Figure 11. Oral Image Figure 12. Intramuscular Image Figure 13. Intranasal Image Figure 14. Others Image Figure 15. Global Vaccine Particulate Adjuvants Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Vaccine Particulate Adjuvants Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Vaccine Particulate Adjuvants Sales Volume Share by Type (2021-2032) Figure 18. Global Vaccine Particulate Adjuvants Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Vaccine Particulate Adjuvants Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Vaccine Particulate Adjuvants Sales Value Share by Type (2021-2032) Figure 21. Infectious Diseases Image Figure 22. Cancer Image Figure 23. Others Image Figure 24. Global Vaccine Particulate Adjuvants Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Vaccine Particulate Adjuvants Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Vaccine Particulate Adjuvants Sales Volume Share by Application (2021-2032) Figure 27. Global Vaccine Particulate Adjuvants Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Vaccine Particulate Adjuvants Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Vaccine Particulate Adjuvants Sales Value Share by Application (2021-2032) Figure 30. Global Vaccine Particulate Adjuvants Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 31. Global Vaccine Particulate Adjuvants Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Vaccine Particulate Adjuvants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Vaccine Particulate Adjuvants Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Vaccine Particulate Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 35. North America Vaccine Particulate Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Vaccine Particulate Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Vaccine Particulate Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Vaccine Particulate Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Vaccine Particulate Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Vaccine Particulate Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 41. South America Vaccine Particulate Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Vaccine Particulate Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Vaccine Particulate Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Vaccine Particulate Adjuvants Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Vaccine Particulate Adjuvants Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous
  • Intradermal
  • Oral
  • Intramuscular
  • Intranasal
  • Others
Applications
  • Infectious Diseases
  • Cancer
  • Others
Companies covered
  • Agenus, Inc(US)
  • Avanti Polar Lipids, Inc(US)
  • Brenntag Biosector (Denmark)
  • CSL Limited (Australia)
  • Invivogen (US)
  • MVP Laboratories, Inc(US)
  • Novavax, Inc(US)
  • OZ Biosciences (France)
  • SEPPIC (France)
  • SPI Pharma, Inc(US)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vaccine Particulate Adjuvants Sales Value (2021-2032)
  4. 1.2.2 Global Vaccine Particulate Adjuvants Sales Volume (2021-2032)
  5. 1.2.3 Global Vaccine Particulate Adjuvants Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vaccine Particulate Adjuvants Market Dynamics
  1. 2.1 Vaccine Particulate Adjuvants Industry Trends
  2. 2.2 Vaccine Particulate Adjuvants Industry Drivers
  3. 2.3 Vaccine Particulate Adjuvants Industry Opportunities and Challenges
  4. 2.4 Vaccine Particulate Adjuvants Industry Restraints
3 Vaccine Particulate Adjuvants Market by Company
  1. 3.1 Global Vaccine Particulate Adjuvants Company Revenue Ranking in 2025
  2. 3.2 Global Vaccine Particulate Adjuvants Revenue by Company (2021-2026)
  3. 3.3 Global Vaccine Particulate Adjuvants Sales Volume by Company (2021-2026)
  4. 3.4 Global Vaccine Particulate Adjuvants Average Price by Company (2021-2026)
  5. 3.5 Global Vaccine Particulate Adjuvants Company Ranking (2024-2026)
  6. 3.6 Global Vaccine Particulate Adjuvants Company Manufacturing Base and Headquarters
  7. 3.7 Global Vaccine Particulate Adjuvants Company Product Type and Application
  8. 3.8 Global Vaccine Particulate Adjuvants Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vaccine Particulate Adjuvants Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vaccine Particulate Adjuvants Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vaccine Particulate Adjuvants Market by Type
  1. 4.1 Vaccine Particulate Adjuvants Type Introduction
  2. 4.1.1 Subcutaneous
  3. 4.1.2 Intradermal
  4. 4.1.3 Oral
  5. 4.1.4 Intramuscular
  6. 4.1.5 Intranasal
  7. 4.1.6 Others
  8. 4.2 Global Vaccine Particulate Adjuvants Sales Volume by Type
  9. 4.2.1 Global Vaccine Particulate Adjuvants Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Vaccine Particulate Adjuvants Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Vaccine Particulate Adjuvants Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Vaccine Particulate Adjuvants Sales Value by Type
  13. 4.3.1 Global Vaccine Particulate Adjuvants Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Vaccine Particulate Adjuvants Sales Value by Type (2021-2032)
  15. 4.3.3 Global Vaccine Particulate Adjuvants Sales Value Share by Type (2021-2032)
5 Vaccine Particulate Adjuvants Market by Application
  1. 5.1 Vaccine Particulate Adjuvants Application Introduction
  2. 5.1.1 Infectious Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Others
  5. 5.2 Global Vaccine Particulate Adjuvants Sales Volume by Application
  6. 5.2.1 Global Vaccine Particulate Adjuvants Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vaccine Particulate Adjuvants Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Vaccine Particulate Adjuvants Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Vaccine Particulate Adjuvants Sales Value by Application
  10. 5.3.1 Global Vaccine Particulate Adjuvants Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Vaccine Particulate Adjuvants Sales Value by Application (2021-2032)
  12. 5.3.3 Global Vaccine Particulate Adjuvants Sales Value Share by Application (2021-2032)
6 Vaccine Particulate Adjuvants Regional Sales and Value Analysis
  1. 6.1 Global Vaccine Particulate Adjuvants Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine Particulate Adjuvants Sales by Region (2021-2032)
  3. 6.2.1 Global Vaccine Particulate Adjuvants Sales by Region: 2021-2026
  4. 6.2.2 Global Vaccine Particulate Adjuvants Sales by Region (2027-2032)
  5. 6.3 Global Vaccine Particulate Adjuvants Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vaccine Particulate Adjuvants Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vaccine Particulate Adjuvants Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vaccine Particulate Adjuvants Sales Value by Region (2027-2032)
  9. 6.5 Global Vaccine Particulate Adjuvants Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vaccine Particulate Adjuvants Sales Value (2021-2032)
  12. 6.6.2 North America Vaccine Particulate Adjuvants Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vaccine Particulate Adjuvants Sales Value (2021-2032)
  15. 6.7.2 Europe Vaccine Particulate Adjuvants Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vaccine Particulate Adjuvants Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vaccine Particulate Adjuvants Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vaccine Particulate Adjuvants Sales Value (2021-2032)
  21. 6.9.2 South America Vaccine Particulate Adjuvants Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vaccine Particulate Adjuvants Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vaccine Particulate Adjuvants Sales Value Share by Country, 2025 VS 2032
7 Vaccine Particulate Adjuvants Country-level Sales and Value Analysis
  1. 7.1 Global Vaccine Particulate Adjuvants Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vaccine Particulate Adjuvants Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vaccine Particulate Adjuvants Sales by Country (2021-2032)
  4. 7.3.1 Global Vaccine Particulate Adjuvants Sales by Country (2021-2026)
  5. 7.3.2 Global Vaccine Particulate Adjuvants Sales by Country (2027-2032)
  6. 7.4 Global Vaccine Particulate Adjuvants Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vaccine Particulate Adjuvants Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vaccine Particulate Adjuvants Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vaccine Particulate Adjuvants Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vaccine Particulate Adjuvants Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vaccine Particulate Adjuvants Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agenus, Inc(US)
  2. 8.1.1 Agenus, Inc(US) Company Information
  3. 8.1.2 Agenus, Inc(US) Business Overview
  4. 8.1.3 Agenus, Inc(US) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Agenus, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  6. 8.1.5 Agenus, Inc(US) Recent Developments
  7. 8.2 Avanti Polar Lipids, Inc(US)
  8. 8.2.1 Avanti Polar Lipids, Inc(US) Company Information
  9. 8.2.2 Avanti Polar Lipids, Inc(US) Business Overview
  10. 8.2.3 Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  12. 8.2.5 Avanti Polar Lipids, Inc(US) Recent Developments
  13. 8.3 Brenntag Biosector (Denmark)
  14. 8.3.1 Brenntag Biosector (Denmark) Company Information
  15. 8.3.2 Brenntag Biosector (Denmark) Business Overview
  16. 8.3.3 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Portfolio
  18. 8.3.5 Brenntag Biosector (Denmark) Recent Developments
  19. 8.4 CSL Limited (Australia)
  20. 8.4.1 CSL Limited (Australia) Company Information
  21. 8.4.2 CSL Limited (Australia) Business Overview
  22. 8.4.3 CSL Limited (Australia) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CSL Limited (Australia) Vaccine Particulate Adjuvants Product Portfolio
  24. 8.4.5 CSL Limited (Australia) Recent Developments
  25. 8.5 Invivogen (US)
  26. 8.5.1 Invivogen (US) Company Information
  27. 8.5.2 Invivogen (US) Business Overview
  28. 8.5.3 Invivogen (US) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Invivogen (US) Vaccine Particulate Adjuvants Product Portfolio
  30. 8.5.5 Invivogen (US) Recent Developments
  31. 8.6 MVP Laboratories, Inc(US)
  32. 8.6.1 MVP Laboratories, Inc(US) Company Information
  33. 8.6.2 MVP Laboratories, Inc(US) Business Overview
  34. 8.6.3 MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  36. 8.6.5 MVP Laboratories, Inc(US) Recent Developments
  37. 8.7 Novavax, Inc(US)
  38. 8.7.1 Novavax, Inc(US) Company Information
  39. 8.7.2 Novavax, Inc(US) Business Overview
  40. 8.7.3 Novavax, Inc(US) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novavax, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  42. 8.7.5 Novavax, Inc(US) Recent Developments
  43. 8.8 OZ Biosciences (France)
  44. 8.8.1 OZ Biosciences (France) Company Information
  45. 8.8.2 OZ Biosciences (France) Business Overview
  46. 8.8.3 OZ Biosciences (France) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 OZ Biosciences (France) Vaccine Particulate Adjuvants Product Portfolio
  48. 8.8.5 OZ Biosciences (France) Recent Developments
  49. 8.9 SEPPIC (France)
  50. 8.9.1 SEPPIC (France) Company Information
  51. 8.9.2 SEPPIC (France) Business Overview
  52. 8.9.3 SEPPIC (France) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 SEPPIC (France) Vaccine Particulate Adjuvants Product Portfolio
  54. 8.9.5 SEPPIC (France) Recent Developments
  55. 8.10 SPI Pharma, Inc(US)
  56. 8.10.1 SPI Pharma, Inc(US) Company Information
  57. 8.10.2 SPI Pharma, Inc(US) Business Overview
  58. 8.10.3 SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  60. 8.10.5 SPI Pharma, Inc(US) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vaccine Particulate Adjuvants Value Chain Analysis
  2. 9.1.1 Vaccine Particulate Adjuvants Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vaccine Particulate Adjuvants Sales Mode & Process
  6. 9.2 Vaccine Particulate Adjuvants Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vaccine Particulate Adjuvants Distributors
  9. 9.2.3 Vaccine Particulate Adjuvants Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst